Atacand vs. Cozaar
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Labeling for AstraZeneca's angiotensin II receptor blocker Atacand (candesartan) may report data showing superior reduction in diastolic blood pressure over Merck's ARB Cozaar (losartan), FDA's Cardiovascular & Renal Drugs Advisory Committee concludes July 18. AstraZeneca's two CLAIM studies showed 1.5 and 2.2 mm Hg greater reductions in DBP for once-daily Atacand vs. once-daily Cozaa
You may also be interested in...
ICER’s Final NASH Report Urges Step Therapy, Specialist Prescribing, Equitable Access
When the first non-alcoholic steatohepatitis drugs reach market, the health cost watchdog says payers will be justified in setting step-therapy including weight-management efforts, while early prescribing should be by specialists.
Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.
ASCO Preview: Five Top Late-Breakers To Watch For
AstraZeneca plans to unveil multiple major data packages, while Servier reveals much-anticipated results in glioma, and ImmunoGen and Novartis will present key pivotal data in women’s cancers.